Protocols

Novartis chief says Trump visa restrictions sour US hiring plans; Parexel and Sanofi to develop wearable devices

→  Don’t look for Novartis CEO Joe Jimenez to add many new jobs in the US anytime soon. In recent interviews the pharma chief says that new visa restrictions advanced by the Trump administration has soured his appetite for any expansion in the US. The company has already felt the effects on hiring foreign nationals. “This makes the country a less attractive location for investment…by contrast, Switzerland and Europe will become more attractive,” he said. Jimenez was one of several industry leaders to meet with the president in January about decreasing drug prices and increasing jobs in the United States.

→  Parexel and Sanofi are teaming up to test wearable devices for remote data collection in clinical trials. They hope to increase patients’ ability to participate, drive patient engagement, and create more opportunities for decentralized trial sites. Sanofi previously began working with wearable device technology to manage diabetes treatment.

→  Mersana says it hopes to raise about $75 million from its IPO by offering five million shares at a price range of $14 to $16 per share.

→  The FDA filed San Francisco-based Rigel’s NDA application for Tavalisse (fostamatinib disodium.) Last year, Rigel struggled with a low response rate in its Phase III trials.

 


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy




EvaluatePharma World Preview 2017